02 Jan
02 Jan
New Commercial Co-Pay Support for EYLEA!
15 Nov
15 Nov
NOW APPROVED—Expanded Dosing Option for EYLEA® (aflibercept) Injection in Wet AMD
06 Jun
06 Jun
REGENERON Announces an Increase in the Wholesale Acquisition Cost (WAC) Discount from 1.1% to 2.5% for Community-Based Physicians, Effective June 11
07 May
07 May
Update on Post-Marketing Reports of Intraocular Inflammation (IOI) Following Administration of EYLEA® (aflibercept) Injection
28 Feb
28 Feb
Update on Intraocular Inflammation (IOI) With Syringes Packaged in Certain Lots of EYLEA┬« (aflibercept) Injection
Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients with DME.

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.